Table 1 The associations between serum ECD level and clinicopathological characteristics in 185 breast cancer patients
From: Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer
Clinical parameters | ECD negative N = 162 | ECD positive N = 23 | ρ value |
|---|---|---|---|
Age (year-old) | |||
< = 50 | 91 (94.8%) | 5 (5.2%) | 0.002* |
> 50 | 71 (79.8%) | 18 (20.2%) | |
Tumor size (cm) | |||
< = 3 | 114 (90.5%) | 12 (9.5%) | 0.080 |
> 3 | 48 (81.4%) | 11 (18.6%) | |
Lymph node status | |||
Negative | 102 (92.7%) | 8 (7.3%) | 0.010* |
Positive | 60 (80.0%) | 15 (20.0%) | |
Stage | |||
0 | 13 (92.9%) | 1 (7.1%) | < 0.0001* |
I | 37 (97.4%) | 1 (2.6%) | |
II | 95 (90.5%) | 10 (9.5%) | |
III | 17 (60.7%) | 11 (39.3%) | |
SBR grade | |||
Low | 81 (92.0%) | 7 (8.0%) | 0.029* |
High | 52 (80.0%) | 13 (20.0%) | |
DNA ploidy | |||
Diploid | 40 (95.2%) | 2 (4.8%) | 0.033*a |
Non-diploid | 69 (80.2%) | 17 (19.8%) | |
Estrogen receptor status (ER) | |||
Negative | 93 (80.9%) | 22 (19.1%) | 0.0002*a |
Positive† | 69 (98.6%) | 1 (1.4%) | |
Progesterone receptor status (PR) | |||
Negative | 107 (83.6%) | 21 (16.4%) | 0.015*a |
Positive | 55 (96.5%) | 2 (3.5%) | |
HER2/neu expression (IHC) | |||
Negative or Weak | 43 (100.0%) | 0 (0.0%) | 0.003*a |
Strong (> = 3+) | 119 (83.8%) | 23 (16.2%) |